Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bbbiotech.com, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions.

RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years.

Moderna was just the beginning

RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years.
30.08.2022 - Daniel Koller

Alnylam, a stock in BB Biotech's portfolio, made its biggest one-day gain since the company went public in June of 2004. Alnylam shares were marked up 60%, reaching a new all-time high, in reaction to the publication of promising data from a pivotal trial of patisiran, an active substance the company is testing on patients with transthyretin amyloid cardiomyopathy. ATTR cardiomyopathy (ATTR-CM) is a rare inherited disease which is characterized by a buildup of faulty amyloid deposits, causing irreversible damage to the heart and nerves, as well other organs or tissues. The life expectancy of a typical patient is less than five years from diagnosis.

Alnylam will present detailed trial results at a medical conference in September and plans to file for regulatory approval in this indication by the end of the year.

The euphoric reaction of financial markets to this news reflects consensus expectations that patisiran will deliver billions in annual peak sales in this indication. Patisiran was already approved for the treatment of the polyneuropathy of ATTR amyloidosis four years ago and is sold under the brand name Onpattro. Alnylam reported annual sales of USD 475 mn from this drug in 2021. Some 50 000 individuals worldwide are affected by ATTR amyloidosis, and Onpattro could be prescribed to treat an additional 300 000 adults with ATTR-CM.

Commercial breakthrough a reality
Alnylam is considered to be one of the most promising takeover candidates in the biotech industry today. The company is marketing four authorized products and will present pivotal clinical trial data on five pipeline candidates by the end of 2023, including Phase III data for fitusiran, an investigational RNA interference treatment for people with hemophilia that Alnylam is developing in collaboration with Sanofi. However, the most compelling takeover argument from an acquirer's perspective is Alnylam's status as a pioneer and market leader in the field of small interfering RNA (siRNA) technology. This is a therapeutic approach that utilizes double-stranded RNA molecules to block the mechanisms of target proteins that have been identified as triggers for certain diseases. Simply put, messenger RNA (mRNA), i.e., the genetic blueprint encoding disease-causing proteins, is effectively suppressed to inhibit the production of those proteins.

RNAi (RNA interference) is a natural biological process for silencing or inhibiting gene expression. siRNAs are one class of RNAi mediators. Antisense technology is a related field where scientists are utilizing short single-stranded nucleic acids, or antisense oligonucleotides, to detect and eliminate disease-causing proteins. Ionis Pharma, a US biotech company, is a pioneer in the field of antisense that has been a core fixture of BB Biotech's portfolio for years. Messenger RNA, or mRNA for short, on the other hand, is a different therapeutic approach that instructs cells to make certain proteins. mRNA technology achieved a major commercial breakthrough with the development and marketing approval of COVID-19 vaccines in less than a year’s time. These mRNA vaccines train the body's immune system to detect viral proteins and develop an effective response without actually getting sick. The two COVID-19 vaccines developed by Moderna and Pfizer/Biontech were crucial in containing the coronavirus pandemic.

RNA technology enters a new chapter
BB Biotech recognized the medical potential of RNA technology early on. There are a total of four RNA-focused companies, including two core shareholdings, Moderna and Ionis, in its portfolio with an aggregate weighting of around 25%. The double-digit price gains of these companies in response to the breakthrough at Alnylam also helped BB Biotech's share price to gain 10% during the same period. In addition to Alnylam’s gains, the value of our stake in Wave Life Sciences rose by 50%. This markup was triggered by the company’s announcement that clinical trials of drugs in genome-editing therapies would begin next year.

Looking ahead to the next few years, we expect RNA-based drugs to enter a new market phase. Under the assumption, of course, that the later-stage testing is likewise successful, the range of potential applications for RNA-based therapeutics would grow to include diseases that affect large patient populations, for example cardiovascular diseases, metabolic disorders, cancer and organ fibrosis. Innovative products that make it to the market will generate billions in revenues.